News from biomarin pharmaceutical inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 05, 2022, 16:04 ET BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company hired two pharmaceutical industry leaders in their respective areas of...

May 05, 2022, 08:29 ET BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an...

May 04, 2022, 09:00 ET BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the...

Apr 27, 2022, 16:02 ET BioMarin Announces Record Revenues in First Quarter 2022

BioMarin Reports Record First Quarter Total Revenues of $519 Million Driven by a $20 Million VOXZOGO Contribution; Total Revenues Grew 11%...

Apr 13, 2022, 09:00 ET BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...

Mar 17, 2022, 08:31 ET BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced publication of results from the Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an...

Feb 23, 2022, 16:03 ET BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended December 31, ...

Feb 17, 2022, 16:05 ET BioMarin Provides Updates on Progress in Gene Therapy Programs

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on its investigational gene therapy programs in clinical development. In February 2022, ...

Feb 16, 2022, 16:00 ET BioMarin to Participate in Two Upcoming Virtual Investor Conferences

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of ...

Feb 10, 2022, 09:00 ET BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...

Feb 09, 2022, 08:31 ET BioMarin Sells Priority Review Voucher for $110 Million

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the...

Feb 04, 2022, 11:15 ET BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) 2-4 February

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company presented positive results from a two-year analysis of the Phase 3...

Feb 02, 2022, 16:04 ET BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Company will be presenting data in several presentations on valoctocogene...

Jan 09, 2022, 15:13 ET BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene...

Jan 04, 2022, 06:00 ET BioMarin to Participate in Two Virtual Investor Conferences in January

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at two...

Dec 16, 2021, 16:05 ET BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on developing...

Dec 15, 2021, 16:05 ET BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of...

Nov 30, 2021, 08:45 ET BioMarin to Hold Virtual R&D Day at 11:00am ET Today

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host a virtual R&D Day beginning at 8:00am PT/11:00am ET today, Tuesday, November 30, 2021. BioMarin ...

Nov 29, 2021, 08:30 ET BioMarin to Participate in Two Upcoming Virtual Investor Conferences

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual investor conferences. An audio...

Nov 19, 2021, 10:42 ET BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to...

Oct 27, 2021, 16:05 ET BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, ...

Oct 25, 2021, 08:30 ET BioMarin to Participate in Four Upcoming Virtual Investor Conferences

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual investor conferences. An audio...

Oct 12, 2021, 08:30 ET BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...

Oct 04, 2021, 08:31 ET BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans Harold S. Bernstein, M.D., Ph.D. as Senior...

Sep 06, 2021, 02:00 ET U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307...